RxDoctor Payments Data

Sara Young, NP

Family · Dearborn, MINPI 1992220552

Payments from drug & device makers

$4,779in general payments, 2019–2025

Across 159 payments — averaging $30.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Alnylam Pharmaceuticals Inc.$634
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$431
  • AstraZeneca$353
  • E.r. Squibb & Sons, L.L.C.$328
  • Boehringer Ingelheim$307
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$51311%
  • Food & beverage$4,26689%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,779 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$3,229
Medicare patients
28
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$32,944
XareltoRivaroxaban22$22,447
JardianceEmpagliflozin24$21,269
FarxigaDapagliflozin Propanediol17$14,737
EntrestoSacubitril/Valsartan12$12,891
BrilintaTicagrelor11$8,005
ClopidogrelClopidogrel Bisulfate64$938
Metoprolol Succinate53$551
Carvedilol49$534
Atorvastatin Calcium69$525
Rosuvastatin Calcium28$504
Amlodipine Besylate87$439
Bumetanide15$350
Hydralazine Hcl45$350
Isosorbide Mononitrate ErIsosorbide Mononitrate31$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$96$32,94441 claims
AstraZenecaFarxiga, Brilinta$353$22,74228 claims
Johnson & JohnsonXarelto$82$22,44722 claims
Boehringer IngelheimJardiance$307$21,26924 claims
NovartisEntresto$148$12,89112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.

Other family in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →